Project Grant R01CA296021
Award Date 8/15/25
Completion Date 7/31/29
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $316,873 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop and evaluate a Spanish-language mobile health (mHealth) smoking cessation app. The goal is to extend the reach of the team's previously validated printed smoking cessation intervention for Hispanic/Latinx smokers, a population disproportionately impacted by smoking-related...
- The National Cancer Institute (NCI) awarded a $753,446 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Boston Medical Center Corporation (BMC) to develop and evaluate an intervention to improve cervical cancer screening and follow-up in underserved populations. The intervention, known as DOSE-CC, combines education and quality improvement methods to help clinicians enhance their cervical cancer prevention practices. The goal is to adapt BMC's prior...
- The National Cancer Institute (NCI), through the Cancer Cause and Prevention Research Program (CFDA 93.393), awarded a $2,124,826 Project Grant to President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) to optimize a mobile messaging intervention for increasing colorectal cancer (CRC) screening rates among patients at community health centers. The project aims to use a two-phase process to first determine optimal messaging strategies for maximizing patient engagement...
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Cedars-Sinai Medical Center in California for $762,258. The project aims to develop a natural language processing (NLP)-based feedback system that can provide real-time information to patients and physicians about the discussion of treatment risks and benefits during prostate cancer consultations. The goal is to enhance patient decision-making and improve...
- The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
- This Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to support informed decision-making about human papillomavirus (HPV) vaccination among parents of adolescents in the United States. The $2,834,092 award, made on August 15, 2025, will fund the development and evaluation of an AI-powered chatbot that delivers personalized, evidence-based messages to address individual concerns and communication preferences regarding HPV...
- This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...